Cancer Pain - Pipeline Review, H1 2014 @ http://www.researchmoz.us/cancer-pain-pipeline-review-h1-2014-report.html This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

1. Cancer Pain - Pipeline Review, H1 2014
Cancer Pain - Pipeline Review, H1 2014
Summary
Global Markets Directs, Cancer Pain - Pipeline Review, H1 2014, provides an overview of the Cancer Pains therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued
projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cancer Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration
details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cancer Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and
industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cancer Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cancer Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand
business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Rofile 77
product Description 77
mechanism Of Action 77
r&d Progress 77
tk-641 - Drug Profile 79
product Description 79
mechanism Of Action 79
r&d Progress 79
tapentadol Hydrochloride Er - Drug Profile 80
product Description 80
mechanism Of Action 80
r&d Progress 80
hydromorphone - Drug Profile 83
product Description 83
mechanism Of Action 83
Cancer Pain - Pipeline Review, H1 2014

2. r&d Progress 83
tanezumab - Drug Profile 84
product Description 84
mechanism Of Action 84
r&d Progress 84
saracatinib - Drug Profile 86
product Description 86
mechanism Of Action 86
r&d Progress 86
(morphine + Oxycodone) Cr - Drug Profile 88
product Description 88
mechanism Of Action 88
r&d Progress 88
arx-02 - Drug Profile 89
product Description 89
mechanism Of Action 89
r&d Progress 89
morphine Sulfate Er - Drug Profile 91
product Description 91
mechanism Of Action 91
r&d Progress 91
fulranumab - Drug Profile 93
product Description 93
mechanism Of Action 93
r&d Progress 93
sufentanil - Drug Profile 95
product Description 95
mechanism Of Action 95
r&d Progress 95
dexmedetomidine Hydrochloride - Drug Profile 96
product Description 96
mechanism Of Action 96
r&d Progress 96
fentanyl - Drug Profile 98
product Description 98
mechanism Of Action 98
r&d Progress 98
pgn-202 - Drug Profile 99
product Description 99
mechanism Of Action 99
r&d Progress 99
fentanyl Citrate Sr - Drug Profile 100
product Description 100
mechanism Of Action 100
r&d Progress 100
leconotide - Drug Profile 101
product Description 101
mechanism Of Action 101
r&d Progress 101
dronabinol - Drug Profile 102
product Description 102
mechanism Of Action 102
r&d Progress 102
vby-825 - Drug Profile 103
product Description 103
mechanism Of Action 103
r&d Progress 103
zucapsaicin - Drug Profile 104
product Description 104
mechanism Of Action 104
r&d Progress 104
ang-2002 - Drug Profile 106
product Description 106
mechanism Of Action 106
r&d Progress 106
z-360 - Drug Profile 107
product Description 107
mechanism Of Action 107
Cancer Pain - Pipeline Review, H1 2014

3. r&d Progress 107
ddrnai Program For Cancer-associated Pain - Drug Profile 108
product Description 108
mechanism Of Action 108
r&d Progress 108
nktr-192 - Drug Profile 110
product Description 110
mechanism Of Action 110
r&d Progress 110
buprenorphine Hydrochloride Er - Drug Profile 111
product Description 111
mechanism Of Action 111
r&d Progress 111
af-353 - Drug Profile 112
product Description 112
mechanism Of Action 112
r&d Progress 112
int-0028 - Drug Profile 114
product Description 114
mechanism Of Action 114
r&d Progress 114
dd-04107 - Drug Profile 115
product Description 115
mechanism Of Action 115
r&d Progress 115
qx-314 - Drug Profile 116
product Description 116
mechanism Of Action 116
r&d Progress 116
ifenprodil - Drug Profile 117
product Description 117
mechanism Of Action 117
r&d Progress 117
calpastatin - Drug Profile 118
product Description 118
mechanism Of Action 118
r&d Progress 118
small Molecule To Antagonize Chemokine Receptor For Cancer Pain - Drug Profile 119
product Description 119
mechanism Of Action 119
r&d Progress 119
kls-2010 - Drug Profile 120
product Description 120
mechanism Of Action 120
r&d Progress 120
ph Alpha-1-beta - Drug Profile 121
product Description 121
mechanism Of Action 121
r&d Progress 121
bbi-11008 - Drug Profile 122
product Description 122
mechanism Of Action 122
r&d Progress 122
cpc-703 - Drug Profile 123
product Description 123
mechanism Of Action 123
r&d Progress 123
cancer Pain - Recent Pipeline Updates 124
cancer Pain - Dormant Projects 138
cancer Pain - Discontinued Products 139
cancer Pain - Product Development Milestones 140
featured News & Press Releases 140
feb 18, 2014: Preclinical Data On Angiochem Pain Program Published In Journal Of Clinical Investigation 140
feb 10, 2014: Sorrento Therapeutics Expands Its Exclusive Rights To Cynviloq To Include Australia, Canada And Mexico 140
dec 05, 2013: Orion Settles Patent Dispute Over The Proprietary Drug Precedex 141
jul 29, 2013: Biodelivery Sciences Announces Regulatory Approval Of Onsolis In Taiwan 141
may 10, 2013: Durect Announces Pfizer's Update On Investigational Pain Drug Remoxy 142
may 09, 2013: Purdue Pharma To Present Data Regarding Long-term Opioid Therapy At Aps Annual Meeting 142
Cancer Pain - Pipeline Review, H1 2014

4. apr 05, 2013: Phosphagenics Receives Approval To Conduct Clinical Study Of Oxycodone Patch At Royal Adelaide Hospital 143
apr 03, 2013: Gw Pharma Receives Us Patent Allowance For Delivery Of Sativex Formulation 143
feb 14, 2013: Us Federal Court Validates Cephalons Fentora Patents 144
oct 15, 2012: Biodelivery Sciences Announces Launch Of Breakyl In Eu 144
appendix 145
methodology 145
coverage 145
secondary Research 145
primary Research 145
expert Panel Validation 145
contact Us 146
disclaimer 146
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Cancer Pain - Pipeline Review, H1 2014